Pilgrim's Pride Corporation (PPC) Receives Hold Rating from Jefferies Group LLC

It has a 40.18 P/E ratio. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analysts await Pilgrim's Pride Corporation (NASDAQ:PPC) to report earnings on October, 25.

In an overview of the current analyst recommendations, Buy count is 19 and Overweight is 1 while the number of analysts recommending Sell and Underweight are 1 and 0, respectively.

Over the past five trading sessions shares of Gulfport Energy Corporation (NASDAQ:GPOR) are -0.75%; 18.97% for the month; 1.68% for the last quarter; -16.87% for the past six-months; and -50.31% for the last 12 months.

(NASDAQ:PPC) shares saw light trading volume with 16K shares changing hands on Tuesday. It has underperformed by 21.72% the S&P500. Pilgrim's Pride Corporation (NASDAQ:PPC) has declined 5.02% since October 11, 2016 and is downtrending. Pilgrims Pride Corp New now has $7.21 billion valuation.

Flexion Therapeutics, Inc.is a United States specialty pharmaceutical company. The stock's market capitalization is 7.17B. The Company is involved in the production, processing, marketing and distribution of fresh, frozen and value-added chicken products to retailers, distributors and foodservice operators.

Investors sentiment decreased to 0.92 in Q2 2017. More interesting news about Pilgrim's Pride Corporation (NASDAQ:PPC) were released by: Reuters.com and their article: "Pilgrim's Pride to pay $1 billion for United Kingdom unit of parent JBS" published on September 11, 2017 as well as Globenewswire.com's news article titled: "Pilgrim's Pride Prices $850.0 million Senior Unsecured Notes Offering" with publication date: September 26, 2017. 20 funds opened positions while 39 raised stakes. Harvest Cap Strategies Ltd Liability Com holds 0.69% or 265,000 shares in its portfolio.

COPYRIGHT VIOLATION WARNING: "Pilgrim's Pride Corporation (PPC) Receives Hold Rating from Jefferies Group LLC" was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal.

Pilgrim's Pride Corporation (NASDAQ:PPC) last posted its quarterly earnings results on Wednesday, August 2nd. Utah Retirement System invested in 0% or 9,700 shares. 121,138 are owned by Citigroup. Ig Invest Mgmt Limited has 72,400 shares for 0.04% of their portfolio. The New York-based Quantbot Techs LP has invested 0.06% in Pilgrim's Pride Corporation (NASDAQ:PPC).

Pilgrim's Pride Corporation may be a good fit for your portfolio or it may not, but at least you have a better understanding of the Food - Major Diversified industry, which can help you later on down the road. Meeder Asset Mngmt has 1,892 shares for 0% of their portfolio. Adams Natural Fund Inc owns 81,400 shares or 1.26% of their USA portfolio. Brandywine Glob Inv Management Limited Liability Corp, a Pennsylvania-based fund reported 329,266 shares. The portion of a company's profit allocated to each outstanding share of common stock was $3.56 a share in the trailing twelve months. 21,400 were accumulated by Laurion Cap Mgmt Lp.

Based on the latest notes released to investors, 1 analyst has issued a rating of "buy", 0 analysts "outperform", 5 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Therefore 0 are positive.

10/31/2014 - Pilgrim's Pride Corporation was upgraded to "overweight" by analysts at Stephens. Jefferies maintained the shares of PPC in report on Tuesday, October 3 with "Hold" rating. BMO Capital Markets maintained Flexion Therapeutics Inc (NASDAQ:FLXN) rating on Monday, June 26. The count of Hold ratings in that period was 5. The company was maintained on Tuesday, August 15 by Barclays Capital. BMO Capital Markets has "Buy" rating and $3500 target. Vertical Research lowered shares of Pilgrim's Pride Corporation from a "buy" rating to a "hold" rating in a research note on Tuesday, September 5th.

07/29/2016 - Pilgrim's Pride Corporation had its "market perform" rating reiterated by analysts at BMO Capital Markets. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned "Buy" rating by Needham on Wednesday, September 9. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.11. XEC's profit will be $90.50 million for 30.22 P/E if the $0.95 EPS becomes a reality. After $0.94 actual EPS reported by Pilgrim's Pride Corporation for the previous quarter, Wall Street now forecasts -24.47% negative EPS growth.

Gulfport Energy Corporation (GPOR) opened the session with a $14.47 price tag, later ranging from $14.33 to $14.63, the range at which the stock has traded at throughout the day. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 82.02% since October 11, 2016 and is uptrending. It has outperformed by 17.05% the S&P500. Currently, 409.24 million total shares are owned by the public and among those 358.79 million shares have been available to trade.

Latest News